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Differential regulation of the activity of deleted
in liver cancer 1 (DLC1) by tensins controls
cell migration and transformation
Xuan Cao, Courtney Voss, Bing Zhao, Tomonori Kaneko, and Shawn Shun-Cheng Li1
Department of Biochemistry and the Siebens-Drake Medical Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario,
London, ON, Canada N6A 5C1

The epithelial growth factor receptor plays an important role in
cell migration and cancer metastasis, but the underlying molecular
mechanism is not fully understood. We show here that differential
regulation of the rhodopsin-GTPase-activating (Rho-GAP) activity
of deleted in liver cancer 1 (DLC1) by tensin3 and COOH-terminal
tensin-like protein (cten) controls EGF-driven cell migration and
transformation. Tensin3 binds DLC1 through its actin-binding
domain, a region that is missing in cten, and thereby releases an
autoinhibitory interaction between the sterile alpha motif and
Rho-GAP domains of DLC1. Consequently, tensin3, but not cten,
promotes the activation of DLC1, which, in turn, leads to inactivation of RhoA and decreased cell migration. Depletion of endogenous tensin3, but not cten, augmented the formation of actin stress
fibers and focal adhesions and enhanced cell motility. These effects
were, however, ablated by an inhibitor of the Rho-associated
protein kinase. Importantly, activation of DLC1 by tensin3 or its actin-binding domain drastically reduced the anchorage-independent
growth of transformed cells. Our study therefore links dynamic
regulation of tensin family members by EGF to Rho-GAP through
DLC1 and suggests that the tensin-DLC1-RhoA signaling axis plays
an important role in tumorigenesis and cancer metastasis, and may
be explored for cancer intervention.

C

ell migration is a complex process involving dynamic changes
in the actin cytoskeleton, focal adhesion, cell matrix, cell–cell
adhesion, and extra- and intracellular signal transduction (1). The
rhodopsin (Rho) family small GTPases play a critical role in
extracellular signal-regulated cytoskeletal changes and cell migration (2). The family is composed of 20 mammalian members, with
RhoA, Rac1, and Cdc42 being the most intensively studied and
best characterized (3). A small GTPase cycle between the GTPbound active and GDP-bound inactive states, with their interconversion catalyzed by guanine nucleotide exchange factors (or
GEFs), which promotes GDP exchange for GTP, and by GTPase
activating proteins (or GAPs), which speed up GTP hydrolysis.
Deleted in liver cancer 1 (DLC1) is a Rho-specific GAP that
is recognized as a tumor suppressor and a regulator of cell proliferation and migration (4). Reduced expression of DLC1 is
associated with most solid tumors (5, 6). Restoration of DLC1
expression in the liver, breast, or lung cancer cells inhibits cell
growth (7–9). DLC1 knockdown was shown to promote hepatocellular carcinoma in mice and that reintroduction of DLC1 into
hepatoma cells suppressed tumor growth in situ (10). DLC1
features a sterile alpha motif (SAM) domain (11), a catalytic
Rho-GAP domain (12), and a steroidogenic acute regulatory
protein-related lipid transfer (START) domain implicated in lipid
binding (13). DLC1 functions as a negative regulator of the Rho
small GTPase family and promotes the hydrolysis of GTP-bound
Rho (in particular RhoA), and, to a lesser extent, Cdc42, but
not Rac (7, 14). The full tumor suppressive function of DLC1
requires its Rho-GAP activity as well as its localization to focal
adhesions controlled by tensins (14–16).
Tensins are a family of focal adhesion proteins that play important roles in signal transduction and cytoskeletal reorganization
www.pnas.org/cgi/doi/10.1073/pnas.1114368109

(17). There are four members in the family, namely tensin1, 2, 3,
and 4 (or COOH-terminal tensin-like protein, cten), each containing an Src homology (SH) 2 and a phosphotyrosine-binding
(PTB) domain that allows it to interact with the cytoplasmic tail
of the β-integrins (14). Except for cten, the other tensins contain
an actin-binding domain (ABD)/focal adhesion-binding region
(17). Tensins have been shown to localize DLC1 to integrinmediated focal adhesions through either or both of the PTB and
SH2 domains (14–16). Although deregulation of tensin expression is frequently associated with cancer (18–20), the roles of the
different tensins in tumorigenesis and metastasis remain largely
undefined and, in some cases, controversial. Whereas all four family members are down-regulated in human kidney cancers (21),
elevated cten expression was correlated with thymoma and lung
cancer progression (18, 20). In invasive breast cancer, cten expression correlates with high epidermal growth factor receptor (EGFR)
and human epidermal growth factor receptor 2 levels and metastasis to lymph nodes (22). Both tensin1 and tensin3 have been
shown to regulate cell migration and invasive behavior (21, 23).
The EGFR plays a critical role in cell growth and migration,
and its deregulation is associated with oncogenesis and cancer
metastasis (24). A recent study identified EGF as an important
regulator of dynamic tensin expression. EGF treatment of epithelial cells was shown to decrease tensin3 (or tns3), but increase
cten expression (22). Although this finding links the dynamic
expression of tensin family members to cell migration induced
by EGF, the corresponding signaling pathway and molecular
mechanism have not been elucidated. We show here that both tensin3 and cten signal through DLC1 to control RhoA activity and
cell migration. They, however, exhibit distinct effects on DLC1. We
identified a unique interaction between tensin3 and DLC1 that
serves to release an autoinhibitory interaction in DLC1 and thereby increase its Rho-GAP activity. We further demonstrated that
EGF-driven cell migration and cellular transformation is dependent on the inhibition of DLC1. Our work suggests that DLC1
is a therapeutic target and that future cancer treatment modalities
should consider DLC1 together with the amplification of EGFR
or a related receptor.
Results
An EGF-Induced Tensin3/Cten Switch Controls RhoA Activation and
Trafficking. To elucidate the mechanism of EGF-induced mammary

cell migration, we first confirmed that the mRNA levels for tensin3
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and cten indeed change with EGF treatment in MCF10A cells
(22). Using real-time PCR, we showed that EGF (10 ng∕mL)
stimulation led to a decrease in the tensin3 and a concomitant increase in the cten transcript (Fig. S1). Because DLC1 is a Rhospecific GAP capable of binding tensins (14, 15), we suspected that
DLC1 might be a target of EGF or the tensin3/cten switch. The
former possibility was eliminated because EGF did not induce a
significant change in the dlc1 transcript (Fig. S1). To test the latter
possibility, we examined the interaction of DLC1 with tensin3 and
cten in MCF10A cells where all three proteins are expressed
(Fig. S2). Robust interactions between DLC1 and both tensins
were observed (Fig. 1A).
Because DLC1 is capable of binding to either tensin3 or cten,
we reasoned that the EGF-induced tensin3/cten switch might
regulate RhoA activity through DLC1. To test this hypothesis, we
examined whether EGF treatment would affect RhoA activation.
Indeed, EGF induced a drastic change in RhoA-GTP, but not the
total RhoA level (Fig. 1B). The marked increase in RhoA activation was not caused by differential expression of DLC1 because
neither its mRNA nor protein level was altered by EGF (Fig. 1B
and Fig. S1). Instead, it could be due to the dynamic changes in the
tensin3 and cten levels (Fig. 1B). As expected, EGF treatment led
to robust EGFR and ERK phosphorylation (22) (Fig. 1B).
In keeping with the biochemical data, confocal microscopy
showed DLC1 colocalization with tensin3 in untreated cells, but
with cten in EGF-treated cells (Fig. 1C). To further characterize
the EGF-induced RhoA activation, we immunostained activated
RhoA and total RhoA, respectively, using specific antibodies.
Robust RhoA activation was seen in the EGF-treated MCF10A
cells, but not in the untreated cells (Fig. 1D). Moreover, RhoAGTP was found dispersed in the periphery of the cytosol or concentrated in areas of protrusions in cells that were apparently

A

undergoing randomized migration (Fig. 1D, Lower), which is in
stark contrast to the localization pattern of RhoA (Fig. 1E). A
specific antibody detected RhoA in both the cytosol and the nuclei
(as puncta) regardless of EGF treatment (Fig. 1E). Presumably
the nuclear form of RhoA was GDP bound because it was undetectable by the RhoA-GTP-specific antibody (Fig. 1D). Therefore,
EGF not only activates RhoA but mobilizes it from the nucleus
to the cytosol or the plasma membrane.
Tensin3 and Cten Oppositely Regulate RhoA Activation via DLC1.

The correlation between the tensin3/cten switch and RhoA activation suggests that the two tensin family members may have distinct effects on RhoA activity. To interrogate this possibility, we
deleted tensin3, cten, and DLC1, either individually or in combination, by siRNA-mediated knockdown in MCF10A cells or
by overexpression (OE) in HEK293 cells deficient in these proteins (Fig. S2). Whereas the depletion of cten led to a marked
reduction in RhoA activation, knockdown of tensin3 resulted
in a drastic increase in the RhoA-GTP level in MCF10A cells
(Fig. 2 A and B). The opposing effects of tensin3 and cten on
RhoA activation are dependent on DLC1 because knockdown
of DLC1 together with either had the same effect on RhoA activation as DLC1 knockdown alone (Fig. 2 C–E). These data indicate that the tensin3/cten switch impinges on DLC1 to control
RhoA activation. This assertion was corroborated by data obtained from HEK293 cells. Whereas overexpression of DLC1
alone had a weak effect on RhoA inactivation, overexpression
of either tensin3 or cten had little effect. Coexpression of cten
and DLC1 also showed a negligible effect on RhoA activity.
Intriguingly, coexpression of tensin3 and DLC1 led to a marked
decrease in the RhoA-GTP level, indicating that tensin3 is an activator of the DLC1 GAP function (Fig. 2F).
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Fig. 1. EGF induces a tensin3/cten switch that leads
to RhoA activation via DLC1. (A) Endogenous DLC1
binds to tensin3 and cten in MCF10A cells. Tensin3
and cten were respectively immunoprecipitated from
cell lysate and immunoblotted for DLC1 (Top). IgG,
nonspecific IgG control. The blot was stripped and reprobed for cten (Middle) or tensin3 (Bottom). (B) The
effect of EGF treatment on the protein levels of DLC1,
cten, and tensin3 and on the activation of RhoA, ERK,
and EGFR. Serum-starved MCF10A cells were incubated for 12 h with EGF (10 ng∕mL). Immunoblots
(IB) of the whole cell lysates (WCL) were used to assess
the protein levels. Rhotekin-conjugated beads were
used to pull down activated RhoA, followed by IB with
anti-RhoA. ERK activation was examined using an
antibody specific for phosphorylated ERK (p-ERK).
EGFR activation was assessed by IB with 4G10 (antipTyr). (C) Colocalization of DLC1 with tensin3 or cten
in MCF10A cells before or after EGF treatment. Confocal images were taken for serum-starved MCF10A
cells before (-EGF) or after 24 h (+EGF) of EGF treatment. (D and E) Confocal immunofluorescence analysis of RhoA-GTP (D) and total RhoA (E) in serumstarved MCF10A cells before or after EGF treatment.
(Scale bars: 10 μm.) Images shown are representative
of at least three independent experiments.
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Tensin3 Activates DLC1 Rho-GAP Function by Releasing an Autoinhibitory Interaction. It was recently shown that the GAP activity of
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DLC1 is controlled by its SAM domain that functions as an
autoinhibitory switch (25). It is therefore likely that the binding
of tensin3 to DLC1 releases this autoinhibition to enhance GAP
function. To interrogate this possibility, we generated expression
constructs that encoded, respectively, the full-length DLC1
(DLC1-FL), the SAM domain (DLC1-SAM), or a truncated version in which the SAM domain was deleted (i.e., DLC1∆SAM)
(Fig. S3) and transfected each into HEK293 cells. Rhotekin
pull-down assays were performed (14) in cells expressing the different proteins. Compared to DLC1-FL, which had a weak
effect, the DLC1∆SAM exhibited a strong inhibitory effect on
RhoA activation (Fig. 3A). Intriguingly, coexpression of the
SAM domain with the DLC1∆SAM mutant completely reversed

A

C
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Fig. 2. Effects of cten, tensin3, and DLC1 knockdown
or overexpression on RhoA activation. (A–E) Effects of
siRNA-mediated depletion of cten, tensin3, and DLC1,
individually or in combination, on RhoA activation in
MCF10A cells. The efficiency of depletion was confirmed by the corresponding immunoblots (IB). RhoA
activation was assessed by Rhotekin affinity pulldown followed by an anti-RhoA IB. Scrambled siRNA
control, siCtrl. (F) Effects of overexpressing cten, tensin3, and DLC1, individually or in combination, on
RhoA activity in HEK293 cells. HEK293 cells were transfected with indicated constructs and the corresponding whole cell lysates (WCL) were analyzed for RhoA
activation. Data shown are representative of three independent experiments.

the effect of the latter on RhoA, indicating that the DLC1
Rho-GAP activity is inhibited by an intramolecular interaction
involving its SAM domain (25) and that loss of this inhibition
leads to enhanced GAP activity (Fig. 3A).
Our observation that exogenous SAM could reestablish the
inhibition in the DLC1ΔSAM mutant suggests that the former
may directly bind to the Rho-GAP domain. To test this possibility,
we used purified GST-DLC1-SAM to pull down either DLC1 or a
truncated version of the protein (ie., DLC1∆SAM, DLC1-RhoGAP-START, DLC1-Rho-GAP, and DLC1-START) (Fig. S3). A
specific interaction between the SAM and Rho-GAP domains
was observed (Fig. 3B). Therefore, the DLC1 SAM domain binds
directly to the Rho-GAP domain to inhibit its activity.
Because tensin3, but not cten, activates DLC1-Rho-GAP,
and because the two tensins differ only in the N-terminal region

B

D

Fig. 3. The tensin3 ABD binds to the SAM domain of
DLC1 to activate its Rho-GAP function. (A) Effects of
the FL and different segments of DLC1 on RhoA activation, respectively. HEK293 cells were transfected
with indicated constructs and the corresponding
whole cell lysates (WCL) were analyzed for RhoA activation. An aliquot of the WCL was subjected to immunoblot (IB) analysis with anti-FLAG and anti-RhoA
to show the levels of the FLAG-tagged proteins and
the total RhoA. (B) The SAM domain binds to the
Rho-GAP domain in DLC1. HEK293 cells transfected
with the indicated constructs were subjected to
pull-down with glutathione beads coupled to GSTDLC1-SAM or GST alone, and the bound proteins were
separated by SDS-PAGE and detected by IB with antiFLAG (Top). The GST proteins were verified by probing
the membrane with anti-GST antibody (Middle). The
expression levels of the different constructs were assayed by an anti-FLAG blot (Bottom). (C) The DLC1
SAM domain binds to the tensin3 ABD domain.
HEK293 cells transfected with the indicated constructs
were subjected to pull-down with GST-DLC1-SAM. The
bound proteins were detected in an anti-GFP blot. (D)
The ABD domain of tensin3 is sufficient for activating
DLC1. The FL or a truncated version of tensin3 (as GFP
fusion) was coexpressed with DLC1-FLAG in HEK293
cells and the effect on RhoA activity was subsequently
assessed. Similar levels of GFP proteins and total RhoA
were confirmed by the corresponding immunoblots.
All scanned films are representative of three independent experiments.
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(Fig. S3), we predicted that the ABD of the former would interact
with the SAM domain to release the autoinhibitory interaction
in DLC1. To test this prediction, we used purified GST-DLC1SAM to pull down GFP-fused cten, tensin3, a tensin3 mutant
with the ABD deleted (tns3∆ABD), or the ABD alone expressed
in HEK293 cells. As seen in Fig. 3C, the SAM domain bound
to FL and the ABD segment, but not to cten or the tns3∆ABD
mutant, indicating that the tensin3 ABD is capable of binding to
the DLC1 SAM domain. To examine whether this interaction is
responsible for releasing the autoinhibition in DLC1, DLC1FLAG was coexpressed, respectively, with cten, tensin3, or the
tensin3-ABD or the tensin3∆ABD mutant. The resulting cell
lysates were then subjected to pull-down by Rhotekin. We found
that the effect of tensin3 on DLC1 activation, and subsequently,
RhoA inactivation, was completely abolished by the deletion of
the ABD (as in the tns3∆ABD mutant). In contrast, ABD alone
exhibited the same effect as the FL tensin3 in activating DLC1
(Fig. 3D). Based on these data, we conclude that the ABD-SAM
interaction competes for the intramolecular SAM-Rho-GAP
interaction to enhance the GAP activity of DLC1, resulting in
and decreasing the RhoA-GTP cellular level.
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The Tensin3/Cten-DLC1 Interactions Differentially Regulate the Actin
Cytoskeleton and Focal Adhesion. As DLC1 is a Rho-specific

GAP, we anticipated that a change in its cellular level would affect
both focal adhesion and stress fiber formation. Indeed, when
DLC1 is depleted from MCF10A cells, a marked increase in focal
adhesions (identified by paxillin staining) and actin stress fibers
(visualized by phalloidin staining) were observed, compared to
cells transfected with the control siRNA (Fig. 4A). Because Rhoassociated protein kinase (ROCK) functions downstream of RhoA
(26), we investigated whether its inhibition would alter focal adhesion and actin stress fiber formation. Indeed, a ROCK-specific
inhibitor, Y27632, was able to abolish the effect of DLC1 depletion. In the presence of the inhibitor, both focal adhesion and
actin staining were drastically weakened. The ROCK inhibitor
also blocked the formation of actin stress fibers induced by EGF
(Fig. S4), reinforcing the notion that EGF signals to RhoA to control reorganization of the cytoskeleton.
Because tensin3 and cten exhibit distinct effects on DLC1
activity, we wondered whether the loss or gain of either tensin
protein would alter focal adhesions and/or actin stress fibers. Depletion of cten abolished the focal adhesions even in cells treated
with EGF, implying that cten is necessary for the formation of
focal adhesions. Actin staining in these cells was restricted to
the cell cortex (Fig. 4B). In contrast, knockdown of tensin3 led to
a marked increase in focal adhesions and actin stress fibers—an
effect that was abolished by Y27632 (Fig. 4C). To test whether
ectopic expression of cten or tensin3 is sufficient to alter actin
stress fiber formation, we transfected MCF10A cells with plasmids encoding GFP, GFP-tensin3 (FL), GFP-cten (FL), GFPtensin3∆ABD, or GFP-tensin3-ABD. Although GFP alone did
not show an apparent effect on the actin cytoskeleton structure,
ectopic expression of tensin3 or tensin3-ABD led to shrinking and
rounding of the cell, and the formation of thick cortical actin bundles (Fig. S5). In contrast, cells that expressed GFP-cten or GFPtensin3∆ABD were characterized with an elongated morphology
and more actin stress fibers formed across the cell body (Fig. S5).
All these results demonstrate that tensin3 and cten differentially
regulate focal adhesion and the actin cytoskeleton via DLC1.
The Tensin3/Cten-DLC1 Interactions Play Distinct Roles in Cell Migration. We next examined the motility, by the Boyden chamber cell

migration assay (22), of MCF10A cells in which the cellular level
of tensin3, cten, or DLC1 was altered. As expected, the rate of
migration for the control cells was greatly enhanced by EGF treatment. However, EGF-induced cell migration was largely abolished
with the knockdown of cten (Fig. 5A). In contrast, depletion of
1458 ∣

www.pnas.org/cgi/doi/10.1073/pnas.1114368109

DLC1

A

paxillin

actin

Merge

paxillin

actin

Merge

paxillin

actin

Merge

siCtrl

siDLC1

siDLC1
Y27632

cten

B
siCtrl

siCten
+EGF

C

tns3

siCtrl

siTns3

siTns3
Y27632

Fig. 4. Effects of cten, tensin3, and DLC1 depletion on the formation of
ROCK-mediated actin stress fibers and focal adhesions in MCF10A cells. (A) Depletion of DLC1 by siRNA resulted in a marked increase of actin stress fibers
and focal adhesions, an effect that was eliminated by the addition of Y27632, a
ROCK inhibitor (10 μM for 1 h). (B) Depletion of cten in EGF-treated (10 ng∕mL)
MCF10A cells led to decreases in stress fibers and focal adhesions. (C) Depletion
of tensin3 in resting MCF10A cells led to enhanced levels of stress fibers and
focal adhesions. The effect, however, was blocked by Y27632. Confocal microscopy images shown are representative of at least three independent experiments. (Scale bars: 10 μm.) Scrambled siRNA control, siCtrl.

either tensin3 or DLC1 resulted in dramatic increases in cell migration even in the absence of EGF. These changes were, however,
abolished by Y27632 (Fig. 5A). Together these data demonstrate
that EGF promotes cell migration by controlling the cellular levels
of tensin3 and cten which, in turn, control DLC1 Rho-GAP activity. The dependence of EGF-induced cell migration on the tensin3/
cten-DLC1 pathway was confirmed in A549 cells that lack DLC1
(Fig. S2). Depletion of cten or tensin3 had negligible effect on the
motility of these cells (Fig. S6).
The Effect of the Tensin3/Cten-DLC1 Interactions on Cellular Transformation. DLC1 is a tumor suppressor, but the role of tensin3 or cten

in tumorigenesis is less well defined (18–23). To address whether
the tensin3/cten-DLC1 complexes play a role in tumorigenesis, we
examined ability of colony formation in soft agar by HEK293 cells
that were made to express full-length or a truncated versions of
Cao et al.
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Fig. 5. The tensin3/cten-DLC1 signaling pathway regulates cell migration
and anchorage-independent cell growth. (A) Tensin3 and cten regulates
cell migration via DLC1. MCF10A cells were transfected with the indicated
siRNA oligos to deplete the corresponding proteins and plated in transwell
chambers containing full medium without or with EGF (10 ng∕mL) and
Y27632 (10 μM). Percentage of migrating cells relative to cells with EGF stimulation was presented. Data shown are mean  SD, n ¼ 9. (B) DLC1 plays a
key role in cellular transformation. HEK293 cells were transfected with the
indicated constructs and incubated for 21 d in soft agar. The number of
colonies formed for cells transfected with a specific construct was compared
to that of the negative control cells, and the resulting percentage number
was presented, with error bars representing standard deviation (SD, n ¼ 3).
Scrambled siRNA control, siCtrl.

DLC1, tensin3, or cten, individually or in various combination.
Whereas the expression of DLC1 led to a significant reduction of
the number of colonies formed, DLC1∆SAM essentially ablated colony formation in soft agar. As expected, coexpression of the SAM
domain with DLC1∆SAM had the same effect as DLC1 itself, suggesting that activation of DLC1 is conducive to inhibition of tumor
formation. Of note, although the expression of either tensin3 or cten
alone had no effect, coexpression of tensin3 with DLC1 strongly
inhibited colony formation. Importantly, coexpression of the ABD
with DLC1 had the same inhibitory effect on anchorage-independent
cell growth as coexpression of DLC1 and tensin3, which is in contrast
to cten which showed no added effect on colony formation when
it was coexpressed with DLC1 (Fig. 5B and Fig. S7). These results
indicate that the tumor suppressive function of tensin3 is dependent
on its ability to promote DLC1 Rho-GAP activity via the ABD
domain. It is likely that the overall RhoA activity controlled by
DLC1-tensin3/cten signaling axis underlie the transformation ability
of HEK293 cells that overexpress these proteins.
Discussion
We show here that EGF-driven cell migration involves the dynamic expression of tensin3 and cten that differentially regulate
DLC1 Rho-GAP activity (Fig. 6). Unstimulated cells are characterized with a higher level of tensin3 than cten (22). Whereas cten
has no apparent effect, tensin3 activates the Rho-GAP activity of
DLC1 through binding of its ABD to the SAM domain of the
latter, thereby releasing an autoinhibitory interaction of DLC1.
Activation of DLC1 results in rapid hydrolysis of RhoA-GTP
to RhoA-GDP and the down-regulaiton of ROCK activity, ultimately leading to reduced stress fibers and the dissociation of
focal adhesions, which are characteristic of resting cells. In the
presence of EGF, however, the dynamics is reversed. Activation
Cao et al.

of the EGFR leads to enhanced phosphorylation and nuclear
translocation of ERK. Phospho-ERK may function as the transcription factor to up-regulate the transcription of cten, but downregulate tensin3. Cten subsequently replaces tensin3 to recruit
DLC1 to the sites of focal adhesions but without activating its
Rho-GAP function, allowing the accumulation of RhoA-GTP
that is generated by a yet-to-be-identified GEF. Activated RhoA
stimulates ROCK activity to drive the formation of actin stress
fibers and focal adhesions, leading to cell migration (Fig. 6) (26).
Although the current work focuses on the role of RhoA in EGFinduced cell migration, it should be pointed out that other signaling pathways such as the PI3K-Akt pathway may contribute to
this process via regulating the activation of Rac and Cdc42 (27).
One of the most intriguing findings of our work is that
EGF-induced tensin3/cten switch impinges on DLC1 to regulate
mammary cell migration. Depletion of DLC1 by siRNA renders
MCF10A cells irresponsive to EGF stimulated cell migration and
accordingly, knockdown of tensin3 or cten has no effect on the
migration of A549 cells that lack DLC1. Our study therefore identifies DLC1 as an important marker for metastatic cancer. Because
DLC1 is a tumor suppressor frequently deleted in cancers (4), we
suggest that deletion of DLC1 or dynamic expression of tensins
with DLC1 predicts cancer outcome. For cancers in which both
the EGFR family and the DLC1 are expressed, one would expect
overexpression of cten and reduced expression of tensin1, 2, and 3
because they contain an ABD domain (Fig. S3). We found this expectation to be indeed the case for a cohort of human colorectal
adenomas (28) in which normal levels of DLC1 and EGFR family
receptors, but elevated cten and reduced tensin1 and tensin3
levels, are observed (Table S1). Similarly, we noticed elevated
DLC1, ErbB2, and cten expression, but reduced tensin1, 2, and
3 expression, in a cohort of breast cancer stroma samples compared to the controls (29) (Table S2).
Because of the strict dependence of EGF-dependent mammary cell migration on DLC1, our study provides an alternative
strategy for cancer intervention targeting DLC1 to conventional
methods that aims to inhibit EGFR signaling (30). We show that
DLC1 alone is not an effective tumor suppressor because it only
moderately reduced colony formation in soft agar (Fig. 5B). However, expression of an active form of DLC1 (i.e., DLC1ΔSAM) or
coexpression of an activator such as tensin3 essentially ablated
anchorage-independent cell growth. Importantly, the ABD fragment of tensin3 had the same effect in inhibiting cellular transformation as the full-length protein. Aberrant activation of RhoA
has been implicated in oncogenesis, and loss of DLC1 may lead to
hyperactivation of RhoA, resulting in enhanced cell migration
(31). Our study raises the possibility that the ABD or a smaller
fragment that is capable of activating DLC1 may be harnessed to
treat cancers associated with aberrant Rho activity (32, 33).
Experimental Procedures
RhoA Activation Assay. RhoA activities were measured using the

Rho Activation Assay Biochem Kit (Cytoskeleton). Cells at 40–60%
confluency were treated with EGF (10 ng∕mL) or transfected with
the indicated siRNA or plasmids. After culturing for 24 h, the cells
were washed with ice-cold PBS and lysed. Equal amounts of whole
cell lysates were incubated with 20 μg GST-Rho-binding domain of
Rhotekin beads for 1 h at 4 °C. The beads were washed three times
with Washing Buffer, and the bound Rho proteins were analyzed by
Western blots using an anti-Rho antibody (Cytoskeleton).
Confocal Microscopy. MCF10A cells grown in 35-mm glass bottom
dishes (P35G-1.0-14-C; MatTek) were transfected with appropriate expression constructs or siRNA oligos and incubated for 24 h
at 37 °C in 5% CO2 . Cells were then fixed as described previously
(14). After rinsing with PBS, cells were incubated with anti-DLC1
rabbit or goat polyclonal (Santa Cruz, 1∶100), anti-tns3 rabbit
(Sigma-Aldrich, 1∶200), or goat (Santa Cruz, 1∶100) polyclonal,
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Fig. 6. A model for the tensin3/cten-DLC1-RhoA signaling axis in regulating EGF-driven cell migration.
Prior to EGF stimulation, mammary cells (such as
MCF10A) express more tensin3 than cten. The RhoGAP activity of DLC1 is inhibited by an intramolecular
interaction with its SAM domain. However, binding
of tensin3 ABD to the SAM domain releases this inhibition, resulting in an increase in DLC1 Rho-GAP activity, which, in turn, leads to a decrease in the RhoAGTP level and destabilization of focal adhesions (FA)
and stress fibers (SF). EGF treatment activates EGFR
and ultimately, ERK. Phosphorylated ERK down-regulates tensin3, but concomitantly up-regulates cten
expression. Without an ABD, cten is incapable of releasing the autoinhibition of DLC1 Rho-GAP activity,
leading to increased RhoA activity and enhanced
formation of focal adhesions and stress fibers, which
together contributes to cell migration. The effect of
the tensin3/cten- DLC1-RhoA signaling axis on cell
migration depends on ROCK.

anti-cten mouse monoclonal (Sigma-Aldrich, 1∶200), anti-paxillin
rabbit polyclonal (Santa Cruz, 1∶100), anti-RhoA rabbit polyclonal
(Santa Cruz, 1∶100) or antiactive RhoA-GTP mouse monoclonal
antibodies (NewEast, 1∶200) for 2 h at room temperature. Samples
were then incubated with the corresponding Alexa Fluor −405,
−488, −546, or −633 conjugated secondary antibodies (InvitrogenMolecular Probes, 1∶1;000) for 1 h followed by incubation with
rhodamine phalloidin (Invitrogen, 1∶50) or DAPI (Calbiochem,
1∶1;000) for 30 min. Samples were visualized with the LSM 510
META or LSM 510 META/Confocor2 confocal microscope (Carl
Zeiss MicroImaging).

Microscope (Motic Incorporation, Ltd.) with Infinity Capture
Imaging system (Lumenera Corporation).
Colony Formation in Soft Agar. HEK293 cells were transfected
with indicated constructs by polyethylenimine and grown overnight. On the following day, cells were trypsinized and plated at
a density of 1 × 104 cells in 0.25% agarose in DMEM (10% FBS),
on top of 0.5% agarose in DMEM (10% FBS) in 60-mm dishes in
triplicate. Cells were maintained at 37 °C in 5% CO2 for 21 d,
and then stained overnight with 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl-tetrazolium bromide. Colonies were counted and the
numbers averaged.

Transwell Cell Migration Assay. Transwell assay was performed as
described previously (22). Photographs of three different fields
of stained cells were captured using Motic AE30/31 Inverted
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